Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
(4) - EconoTimes)
DUBLIN, IRELAND, May 04, 2018 -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2018 of inducement restricted stock units for an aggregate of 228,305 ordinary shares to 30 new employees.
Certain of the restricted stock units vest over four years, with 25 percent of the shares vesting on each anniversary of the applicable vesting commencement date, and certain of the restricted stock units vest over three years, with 1/3 of the shares vesting on each anniversary of the applicable vesting commencement date. All awards are subject to the new employee's continued service relationship with the Company. Each restricted stock unit also is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.
The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with NASDAQ Listing Rule 5635(c)(4).
About Horizon Pharma plc
Horizon Pharma plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it’s personal: by living up to our own potential, we are helping others live up to theirs. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
Contacts:
Tina Ventura
Senior Vice President, Investor Relations
[email protected]
Ruth Venning
Executive Director, Investor Relations
[email protected]
U.S. Media Contact:
Geoffrey Curtis
Senior Vice President, Corporate Affairs and Chief Communications Officer
[email protected]
Ireland Media Contact:
Ray Gordon
Gordon MRM
[email protected]
